Dapagliflozin may improve symptoms in patients with HFrEF with limited impact on exercise capacity
Dapagliflozin may improve symptoms in patients with HFrEF with limited impact on exercise capacity suggests a new study published in the Circulation. Sodium-glucose cotransporter 2 inhibitors reduce the risk of worsening heart failure (HF) and cardiovascular death in patients with HF irrespective of left ventricular ejection fraction. It is important to determine whether therapies for […]